Trader’s Buzzers: ARIAD Pharmaceuticals, Inc. (ARIA), MGIC Investment Corporation (MTG), Infinera Corporation (INFN)

ARIAD Pharmaceuticals, Inc. (ARIA) traded within a range of $23.87 to $23.95 after opening the day at $23.87. The company has seen its stock increase in value by 92.52% so far this year. The stock was up close to 0.42% on light volume in last trading session and closed at $23.95 per share. After the recent gain, the stock is currently holding 0.25% above its 52 week high of $23.95 and 448.05% above its 12-month low of $4.48. The shares are up by over 103.48% in the last three months, and the RSI indicator value of 88.96 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

MGIC Investment Corporation (MTG) continued its upward trend with the stock climbing 0.54% or $0.06 to close the day at $11.26 on active trading volume of 6.23M shares, compared to its three month average trading volume of 5.18M. The Milwaukee Wisconsin 53202 based company has been outperforming the property & casualty insurance group over the past 52 weeks, with the stock gaining 66.08%, compared to the industry which has advanced 27.88% over the same period. With RSI of 66.11, the stock should still continue to rise and get closer to its one year target estimate of $11.83, making it a hold for now.

MGIC Investment Corporation, through its subsidiaries, provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States. The company offers primary mortgage insurance that provides mortgage default protection on individual loans, as well as covers unpaid loan principal, delinquent interest, and various expenses associated with the default and subsequent foreclosure. It also provides contract underwriting services; and other services for the mortgage finance industry, such as analysis of loan originations and portfolios, and mortgage lead generation services. In addition, the company participates in external reinsurance arrangements and captive mortgage reinsurance arrangements. It serves originators of residential mortgage loans, including savings institutions, commercial banks, mortgage brokers, credit unions, mortgage bankers, and other lenders. The company was founded in 1957 and is headquartered in Milwaukee, Wisconsin.

Infinera Corporation (INFN) gained $0.14 to close the day at a new closing price of $12.1, a 1.17% increase in value from its previous closing price that moved the stock 67.36% above its 52 week low of $7.23. A total of 6.17M shares exchanged hands during the day compared with its three month average trading volume of 1.89M. The stock, which fluctuated between $11.55 and $12.5 during the day, currently situated -28.99% below its 52 week high. The stock is up by 39.08% in the past one month and up by 45.26% over the past three months. With a one year target estimate of $8.89 and RSI of 86.34, the stock still has upside potential, making it a sell for now.

Infinera Corporation provides optical transport networking equipment, software, and services worldwide. The company offers Infinera DTN-X family of platforms for subsea, long-haul, regional, and metro mesh networks; Infinera DTN platform for subsea, long-haul, and regional mesh networks that support a range of Ethernet and optical transport network client interfaces; and Infinera FlexILS Line System platform that connects various Infinera platforms over long distance fiber optic cable. It also provides Infinera TM-Series, a carrier-grade packet-optical transport platform; Infinera TS-Series, a passive optical wavelength-division multiplexing (WDM) product; Infinera Cloud Xpress Platform, a compact platform for cloud/data center interconnect applications; and Infinera ATN Platform, a small form-factor WDM platform. In addition, the company offers Infinera Open Transport Switch, a software platform that enables abstraction and virtualization of the underlying Infinera platforms; and Infinera Management Suite, a network management system used by network operators to manage various Infinera platforms. Further, it provides various support services for vraious hardware and software products. The company serves communications service providers, Internet content providers, cable providers, wholesale and enterprise carriers, research and education institutions, and government entities. It markets and sells its products and related support services primarily through its direct sales force. The company was formerly known as Zepton Networks. Infinera Corporation was founded in 2000 and is headquartered in Sunnyvale, California.

 

Momentum Stocks in Focus: Radian Group Inc. (RDN), ARIAD Pharmaceuticals, Inc. (ARIA), MaxLinear, Inc. (MXL)

Radian Group Inc. (RDN) continued its upward trend with the stock climbing 2.53% or $0.48 to close the day at $19.46 on light trading volume of 2.54M shares, compared to its three month average trading volume of 2.68M. The Philadelphia Pennsylvania 19103 based company has been outperforming the property & casualty insurance group over the past 52 weeks, with the stock gaining 83.93%, compared to the industry which has advanced 28.35% over the same period. With RSI of 69.75, the stock should still continue to rise and get closer to its one year target estimate of $20.8, making it a hold for now.

Radian Group Inc., through its subsidiaries, provides mortgage and real estate products and services in the United States. It operates through two segments, Mortgage Insurance, and Mortgage and Real Estate Services (Services). The Mortgage Insurance segment provides credit-related insurance coverage, principally through private mortgage insurance that protects mortgage lenders from all or a portion of default-related losses on residential mortgage loans made to home buyers, as well as facilitates the sale of these mortgage loans in the secondary mortgage market. It offers primary mortgage insurance coverage on residential first-lien mortgage loans. This segment primarily serves mortgage bankers, mortgage brokers, commercial banks, savings institutions, credit unions, and community banks. The Services segment provides outsourced services, information-based analytics, and specialty consulting services for buyers and sellers of, and investors in, mortgage- and real estate-related loans and securities, and other asset-backed securities. This segment offers loan review and due diligence, monitoring of mortgage servicer and loan performance, valuation and component services, real estate owned asset management services, and outsourced mortgage services. Radian Group Inc. was founded in 1977 and is headquartered in Philadelphia, Pennsylvania.

ARIAD Pharmaceuticals, Inc. (ARIA) grew with the stock adding 0.08% or $0.02 to close at $23.89 on active trading volume of 2.53M compared its three months average trading volume of 10.5M. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 418.22% up for the period and up by 92.04% so far this year. With price target of $20.63 and a 446.68% rebound from 52-week low, ARIAD Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

MaxLinear, Inc. (MXL) failed to extend gains with the stock declining -0.97% or $-0.26 to close the day at $26.58 on lower than average trading volume of 2.51M shares, compared to its three month average trading volume of 863.98K. The Carlsbad California 92008 based company has been outperforming the semiconductor – integrated circuits companies by 25.1652% for last three months and its recent gains have pushed the stock slightly up 21.93% YTD, versus the semiconductor – integrated circuits industry which is up 5.54% for the same period. The RSI of 74.74 indicates the stock is overbought at the current levels, sell for now.

MaxLinear, Inc. provides integrated, radio-frequency (RF) and mixed-signal circuits for broadband communication and data center, metro, and long-haul transport network applications worldwide. The company offers RF receivers and RF receiver systems-on-chips to receive and demodulate broadband signals and physical medium devices that provide a constant current source, current-to-voltage regulation, and data alignment and retiming functionality in optical interconnect applications. Its products enable the distribution and display of broadband video and data content in various electronic devices, such as cable and terrestrial and satellite set top boxes, DOCSIS data and voice gateways, hybrid analog and digital televisions, satellite low-noise blocker transponders or outdoor units, and optical modules. The company also offers laser modulator drivers, which delivers the current to the laser diode to operate for a particular application; Transimpedance amplifiers that provide current-to-voltage conversion, converting the low-level current of a sensor to a voltage; and clock and data recovery circuits, which generate a clock from an approximate frequency reference and then phase-aligns to the transitions in the data stream with a phase-locked loop. It sells its products to original equipment manufacturers, module makers, and original design manufacturers through direct sales force, third party sales representatives, and a network of distributors. The company has a strategic partnership with MStar Semiconductor, Inc. to develop reference design for ultra high definition smart cable gateway set-top boxes. MaxLinear, Inc. was incorporated in 2003 and is headquartered in Carlsbad, California.

 

Trader Alert: Naked Brand Group Inc. (NAKD), ARIAD Pharmaceuticals, Inc. (ARIA), Under Armour, Inc. (UA)

Naked Brand Group Inc. (NAKD) grew with the stock adding 25.61% or $0.74 to close at $3.63 on active trading volume of 7.8M compared its three months average trading volume of 1.02M. The New York New York 10016 based company has been trending up for the last 52 weeks, with the shares price now 41.8% up for the period and up by 263% so far this year. With price target of $0 and a 341.93% rebound from 52-week low, Naked Brand Group Inc. has plenty of upside potential, making it a hold with a view buy.

Naked Brand Group Inc. designs, manufactures, and sells men’s and women’s underwear, intimate apparel, loungewear, and sleepwear products in the United States and Canada. It offers various innerwear products for men, including boxer briefs, trunks, briefs, undershirts, T-shirts, lounge pants, lounge shorts, and robes; and loungewear and sleepwear products for women, such as boyshorts, hipsters, lounge pants and tops, camisoles, tank tops, pajamas, chemises, sleepshirts, and robes primarily under the Naked brand name. The company sells its products to consumers and retailers through wholesale channels; and direct-to-consumer channel, which consists of an online e-commerce store, wearnaked.com. Naked Brand Group Inc. is headquartered in New York, New York.

ARIAD Pharmaceuticals, Inc. (ARIA) gained $0.01 to close the day at a new closing price of $23.81, a 0.04% increase in value from its previous closing price that moved the stock 444.85% above its 52 week low of $4.37. A total of 7.79M shares exchanged hands during the day compared with its three month average trading volume of 10.58M. The stock, which fluctuated between $23.79 and $23.82 during the day, currently situated -0.17% below its 52 week high. The stock is up by 73.29% in the past one month and up by 168.13% over the past three months. With a one year target estimate of $20.63 and RSI of 88.58, the stock still has upside potential, making it a sell for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Under Armour, Inc. (UA) shares were down in last trading by -1.93% to $17.79. It experienced higher than average volume on day. The stock decreased in value by almost -7.44% over the past week and fell -34.21% in the past month. It is currently trading -32.03% below its 50 day moving average and -49.71% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -62.9% decrease in value from its one year high of $46.2. The RSI indicator value of 15.22, lead us to believe that it may correct downwards in the near term.

Under Armour, Inc. together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes. It provides various footwear products, including football, baseball, lacrosse, softball and soccer cleats, slides, performance training, running, basketball, and outdoor footwear. The company also offers accessories, which include headwear, bags, and gloves; and digital fitness platform licenses and subscriptions, as well as digital advertising, as well as licenses its brands. It primarily provides its products under the UA Logo, UNDER ARMOUR, UA, ARMOUR, HEATGEAR, COLDGEAR, ALLSEASONGEAR, PROTECT THIS HOUSE, and I WILL, as well as ARMOURBITE, ARMOURSTORM, ARMOUR FLEECE, and ARMOUR BRA trademarks. The company sells its products through wholesale channels, including national and regional sporting goods chains, independent and specialty retailers, department store chains, institutional athletic departments, and leagues and teams, as well as independent distributors; and directly to consumers through a network of brand and factory house stores, and Website. Under Armour, Inc. was founded in 1996 and is headquartered in Baltimore, Maryland.

 

Momentum Stocks in Focus: Actinium Pharmaceuticals, Inc. (ATNM), ARIAD Pharmaceuticals, Inc. (ARIA), Amyris, Inc. (AMRS)

Actinium Pharmaceuticals, Inc. (ATNM) managed to rebound with the stock climbing 32.04% or $0.33 to close the day at $1.36 on active trading volume of 5.51M shares, compared to its three month average trading volume of 274.27K. The New York New York 10017 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -32.67%, compared to the industry which has advanced 10.74% over the same period. With RSI of 74.98, the stock should still continue to rise and get closer to its one year target estimate of $7.33, making it a hold for now.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company’s targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical product candidate is Iomab-B that is in Phase 3 clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase 1/2 clinical trials for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial. Actinium Pharmaceutical, Inc. was founded in 2000 and is headquartered in New York, New York.

ARIAD Pharmaceuticals, Inc. (ARIA) grew with the stock adding 0.04% or $0.01 to close at $23.8 on active trading volume of 5.5M compared its three months average trading volume of 10.71M. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 345.69% up for the period and up by 91.32% so far this year. With price target of $20.63 and a 444.62% rebound from 52-week low, ARIAD Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Amyris, Inc. (AMRS) managed to rebound with the stock climbing 9.11% or $0.04 to close the day at $0.49 on higher than average trading volume of 5.47M shares, compared to its three month average trading volume of 2.37M. The Emeryville California 94608 based company has been outperforming the specialty chemicals companies by -52.5136% for last three months and its recent losses have pulled the stock down -32.74% YTD, versus the specialty chemicals industry which is up 8.23% for the same period. The RSI of 27.14 indicates the stock is oversold at the current levels, buy for now.

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and renewable lubricants for industrial applications; and renewable fuels for transportation fuels market. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

 

Stocks in the Spotlight: ARIAD Pharmaceuticals, Inc. (ARIA), Plug Power Inc. (PLUG), Oclaro, Inc. (OCLR)

ARIAD Pharmaceuticals, Inc. (ARIA) had a active trading with around 11.89M shares changing hands compared to its three month average trading volume of 10.57M. The stock traded between $23.74 and $23.84 before closing at the price of $23.79 with -0.13% change on the day. The Cambridge Massachusetts 02139 based company is currently trading 444.39% above its 52 week low of $4.37 and -0.25% below its 52 week high of $23.85. Both the RSI indicator and target price of 87.37 and $20.63 respectively, lead us to believe that it could drop over the coming weeks.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Plug Power Inc. (PLUG) managed to rebound with the stock declining -3.77% or $-0.04 to close the day at $1.02 on light trading volume of 11.64M shares, compared to its three month average trading volume of 3.67M. The Latham New York 12110 based company has been underperforming the diversified electronics group over the past 52 weeks, with the stock losing -38.92%, compared to the industry which has advanced 40% over the same period. With RSI of 24.14, the stock should still continue to rise and get closer to its one year target estimate of $2.26, making it a hold for now.

Plug Power Inc., an alternative energy technology provider, engages in the design, development, manufacture, and commercialization of fuel cell systems for the material handling and stationary power market in the United States. The company focuses on proton exchange membrane (PEM) fuel cell and fuel processing technologies, and fuel cell/battery hybrid technologies. Its product line includes GenKey, a turn-key solution for transitioning material handling vehicles to fuel cell power; GenDrive, a hydrogen fueled PEM fuel cell system that provides power to material handling vehicles; GenFuel, a hydrogen fueling delivery system; GenCare, which is an ongoing maintenance program for GenDrive fuel cells and GenFuel products; ReliOn, a stationary fuel cell solution that provides scalable and modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors; and GenFund, which offers financing solutions to customers. The company sells its products to businesses and government agencies through direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

Oclaro, Inc. (OCLR) shares were down in last trading by -3.67% to $9.45. It experienced higher than average volume on day. The stock decreased in value by almost -7.44% over the past week and grew 5.59% in the past month. It is currently trading 4.65% above its 50 day moving average and 32.17% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -8.7% decrease in value from its one year high of $10.35. The RSI indicator value of 54.04, lead us to believe that it is a hold for now.

Oclaro, Inc. designs, manufactures, and markets lasers and optical components, modules, and subsystems for the optical communications, industrial, and consumer laser markets worldwide. The company’s products generate, detect, combine, and separate light signals in optical communications networks. It offers client side transceivers, including pluggable transceivers; line side transceivers; tunable laser transmitters, such as discrete lasers and co-packaged laser modulators; lithium niobate modulators to manipulate the phase or the amplitude of an optical signal; transponder modules for transmitter and receiver functions; and discrete lasers and receivers for metro and long-haul applications. The company markets its products through direct sales force, as well as through sales representatives and resellers. It serves network equipment manufacturers of telecommunications and datacom systems, and hyperscale data center operators. The company was formerly known as Bookham, Inc. and changed its name to Oclaro, Inc. in April 2009. Oclaro, Inc. was founded in 1988 and is headquartered in San Jose, California.

 

Stocks Buzz: ARIAD Pharmaceuticals, Inc. (ARIA), Oasis Petroleum Inc. (OAS), Oclaro, Inc. (OCLR)

ARIAD Pharmaceuticals, Inc. (ARIA) failed to extend gains with the stock declining -0.13% or $-0.03 to close the day at $23.65 on active trading volume of 9.17M shares, compared to its three month average trading volume of 10.39M. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 371.12%, compared to the industry which has advanced 1.57% over the same period. With RSI of 86.47, the stock should still continue to rise and get closer to its one year target estimate of $20.63, making it a hold for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Oasis Petroleum Inc. (OAS) retreated with the stock falling -5.71% or $-0.85 to close at $14.04 on active trading volume of 8.72M compared its three months average trading volume of 10.43M. The Houston Texas 77002 based company operating under the Independent Oil & Gas industry has been trending up for the last 52 weeks, with the shares price now 162.43% up for the period and down by -7.27% so far this year. With price target of $17.04 and a 250.12% rebound from 52-week low, Oasis Petroleum Inc. has plenty of upside potential, making it a hold with a view buy.

Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its principal projects are located in West Williston and East Nesson. As of December 31, 2015, the company had 484,745 net leasehold acres in the Williston Basin; and approximately 218.2 million barrels of oil equivalent of estimated net proved reserves. Oasis Petroleum Inc. sells its oil and natural gas to refiners, marketers, and other purchasers that have access to pipeline and rail facilities. The company was founded in 2007 and is headquartered in Houston, Texas.

Oclaro, Inc. (OCLR) continued its downward trend with the stock declining -2.81% or $-0.28 to close the day at $9.68 on higher than average trading volume of 8.44M shares, compared to its three month average trading volume of 6.1M. The San Jose California 95131 based company has been outperforming the semiconductor equipment & materials companies by 28.5947% for last three months and its recent gains have pushed the stock slightly up 8.16% YTD, versus the semiconductor equipment & materials industry which is up 8.03% for the same period. The RSI of 56.73 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Oclaro, Inc. designs, manufactures, and markets lasers and optical components, modules, and subsystems for the optical communications, industrial, and consumer laser markets worldwide. The company’s products generate, detect, combine, and separate light signals in optical communications networks. It offers client side transceivers, including pluggable transceivers; line side transceivers; tunable laser transmitters, such as discrete lasers and co-packaged laser modulators; lithium niobate modulators to manipulate the phase or the amplitude of an optical signal; transponder modules for transmitter and receiver functions; and discrete lasers and receivers for metro and long-haul applications. The company markets its products through direct sales force, as well as through sales representatives and resellers. It serves network equipment manufacturers of telecommunications and datacom systems, and hyperscale data center operators. The company was formerly known as Bookham, Inc. and changed its name to Oclaro, Inc. in April 2009. Oclaro, Inc. was founded in 1988 and is headquartered in San Jose, California.

 

Traders Watch list: ARIAD Pharmaceuticals, Inc. (ARIA), Investors Bancorp, Inc. (ISBC), Hanesbrands Inc. (HBI)

ARIAD Pharmaceuticals, Inc. (ARIA) saw its value increase by 0.17% as the stock gained $0.04 to finish the day at a closing price of $23.68. The stock was lighter in trading and has fluctuated between $4.37-$23.81 per share for the past year. The shares, which traded within a range of $23.63 to $23.75 during the day, are up by 154.35% in the past three months and up by 150.05% over the past six months. It is currently trading 18.96% above its 20 day moving average and 50.22% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $20.63 a share over the next twelve months. The current relative strength index (RSI) reading is 87.38.The technical indicator do not lead us to believe the stock will see more gains any time soon.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Investors Bancorp, Inc. (ISBC) shares were up in last trading by 2.55% to $14.46. It experienced higher than average volume on day. The stock increased in value by almost 4.63% over the past week and grew 2.63% in the past month. It is currently trading 3.84% above its 50 day moving average and 18.68% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a 0.49% increase in value from its one year high of $14.93. The RSI indicator value of 62.74, lead us to believe that it is a hold for now.

Investors Bancorp, Inc. operates as the holding company for Investors Bank that provides community banking products and services to individuals and businesses in the United States. It offers deposit products, such as savings, checking, and money market accounts, as well as certificates of deposit. The company’s loan portfolio includes multi-family, commercial real estate, construction, commercial and industrial, residential mortgage, and consumer and other loans; consumer loans primarily comprising home equity loans, home equity lines of credit, and others; and mortgage loans secured by one-to four-family residential real estate. As of December 31, 2015, the company operated 140 offices located in New Jersey and New York. The company was founded in 1926 and is headquartered in Short Hills, New Jersey.

Hanesbrands Inc. (HBI) traded within a range of $22.88 to $23.73 after opening the day at $23.6. The company has seen its stock increase in value by 6.07% so far this year. The stock was down close to -3.21% on active volume in last trading session and closed at $22.88 per share. After the recent fall, the stock is currently holding -25.79% below its 52 week high of $31.36 and 6.92% above its 12-month low of $21.4. The shares are down by over -3.79% in the last three months, and the RSI indicator value of 52.58 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Hanesbrands Inc., a consumer goods company, designs, manufactures, sources, and sells various basic apparels for men, women, and children in the United States. The company operates through four segments: Innerwear, Activewear, Direct to Consumer, and International. It sells bras, panties, shapewears, hosiery, men’s underwear, children’s underwear, and socks; and other activewear, such as T-shirts, fleece, sport shirts, performance T-shirts and shorts, sports bras, and thermals, as well as licensed logo apparel in collegiate bookstores and other channels. The company licenses its Champion name for footwear and sports accessories. It provides its products primarily under the Maidenform, Bali, Playtex, Hanes, JMS/Just My Size, Lilyette, Wonderbra, Donna Karan, DKNY, Champion, Polo Ralph Lauren, L’eggs, Hanes Beefy-T, Gear for Sports, Duofold, DIM, Nur Die/Nur Der, Lovable, Shock Absorber, Abanderado, Zorba, Rinbros, Kendall, Sol y Oro, Fila, Bellinda, Edoo, and Track N Field brand names. The company markets its products through retailers, wholesalers, and third party embellishers, as well as directly to consumers. As of January 2, 2016, it operated 252 outlet stores in the United States; and Websites under the Hanes, One Hanes Place, JMS/Just My Size, Champion, and Maidenform names. The company also sells its products in Europe, Asia, Latin America, Canada, Australia, the Middle East, Africa, and the Caribbean. Hanesbrands Inc. was founded in 2005 and is headquartered in Winston-Salem, North Carolina.

 

Three Movers to Watch for: InterCloud Systems, Inc. (ICLD), ARIAD Pharmaceuticals, Inc. (ARIA), PulteGroup, Inc. (PHM)

InterCloud Systems, Inc. (ICLD) retreated with the stock falling -6.67% or $0 to close at $0.02 on light trading volume of 14.67M compared its three months average trading volume of 4.32M. The Shrewsbury New Jersey 07702 based company operating under the Information Technology Services industry has been trending down for the last 52 weeks, with the shares price now 0% down for the period and down by -45.98% so far this year. With price target of $0 and a 5% rebound from 52-week low, InterCloud Systems, Inc. has plenty of upside potential, making it a hold with a view buy.

InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally. It operates through four segments: Applications and Infrastructure, Professional Services, Managed Services, and Cloud Services. The company offers various services, including platform as a service, infrastructure as a service, database as a service, and software as a service; and network management, 24x7x365 monitoring, security monitoring, and storage and backup services. It also provides software-defined networking (SDN) training, SDN software development and integration, virtualized network functions validation in a multi-vendor environment, unified communications, interactive voice response, and session initiation protocol based call centers, as well as structured cabling and other field installations. In addition, the company designs, engineers, installs, and maintains various types of Wi-Fi and wide-area, distributed antenna system, and small cell distribution networks for incumbent local exchange carriers, telecommunications original equipment manufacturers (OEMs), cable broadband multiple system operators, and enterprise customers, as well as designs, installs, and maintains hardware solutions for the OEMs that support voice, data, and optical networks. Further, it provides consulting and professional staffing solutions to the service-provider and enterprise market in support of IT and next-generation networks comprising project management, network implementation, network installation, network upgrades, rebuilds, maintenance, and consulting services. Additionally, the company’s engineering, design, installation, and maintenance services support the build-out and operation of enterprise, fiber optic, Ethernet, and wireless networks. InterCloud Systems, Inc. was founded in 2006 and is based in Shrewsbury, New Jersey.

ARIAD Pharmaceuticals, Inc. (ARIA) dropped $-0.08 to close the day at a new closing price of $23.64, a -0.34% decrease in value from its previous closing price that moved the stock 440.96% above its 52 week low of $4.37. A total of 14.18M shares exchanged hands during the day compared with its three month average trading volume of 10.25M. The stock, which fluctuated between $23.63 and $23.73 during the day, currently situated -0.71% below its 52 week high. The stock is up by 93.45% in the past one month and up by 153.1% over the past three months. With a one year target estimate of $20.63 and RSI of 86.71, the stock still has upside potential, making it a sell for now.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

PulteGroup, Inc. (PHM) shares were up in last trading by 3.62% to $21.18. It experienced higher than average volume on day. The stock increased in value by almost 11.83% over the past week and grew 15.23% in the past month. It is currently trading 12.05% above its 50 day moving average and 9.69% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -4.56% decrease in value from its one year high of $22.4. The RSI indicator value of 75.59, lead us to believe that it may reverse gains in the near term.

PulteGroup, Inc., through its subsidiaries, engages primarily in the homebuilding business in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on such land. It offers various home designs, including single-family detached, townhouses, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes John Wieland Homes, and Neighborhoods names. As of March 31, 2016, the company controlled 102,580 owned lots and 43,072 lots under land option agreements. It also arranges financing through the origination of mortgage loans, principally for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was formerly known as Pulte Homes, Inc. and changed its name to PulteGroup, Inc. in March 2010. PulteGroup, Inc. was founded in 1950 and is headquartered in Atlanta, Georgia.

 

Traders Recap: Steel Dynamics, Inc. (STLD), Cree, Inc. (CREE), ARIAD Pharmaceuticals, Inc. (ARIA)

Steel Dynamics, Inc. (STLD) failed to extend gains with the stock declining -6.59% or $-2.39 to close the day at $33.86 on lower than average trading volume of 11.42M shares, compared to its three month average trading volume of 3.86M. The Fort Wayne Indiana 46804 based company has been outperforming the steel & iron companies by 30.3795% for last three months and its recent gains have offset losses to -4.83% YTD, versus the steel & iron industry which is up 4.03% for the same period. The RSI of 38.58 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Steel Dynamics, Inc., together with its subsidiaries, manufactures and sells steel products; processes and sells recycled ferrous and nonferrous metals; and fabricates and sells steel joist and deck products in the United States and internationally. The company operates through Steel Operations, Metals Recycling Operations, and Steel Fabrication Operations segments. The Steel Operations segment provides a range of sheet steel products, such as hot roll, cold roll, and coated steel products; structural steel beams and pilings to construction market; various rail products for the railroad industry; rounds, round-cornered squares, and round engineered bars; angles, merchant rounds, flats and channels, and reinforcing bar; and beams, channels, and specialty steel sections. This segment offers its products for automotive, construction, manufacturing, transportation, heavy and agriculture equipment, and pipe and tube markets. The Metals Recycling Operations segment is involved in the purchase, process, and resale of ferrous and nonferrous scrap metals into reusable forms and grades. Its ferrous products include heavy melting steel, busheling, bundled scrap, shredded scrap, steel turnings, and cast iron products; and nonferrous products comprise aluminum, brass, copper, stainless steel, and other nonferrous metals. This segment also provides transportation logistics, management, marketing, brokerage, and consulting services related to the scrap industry. The Steel Fabrication Operations segment produces steel building components comprising steel joists, girders, trusses, and steel decks primarily for the non-residential construction industry. The company also produces pig and hot briquetted iron; and iron nugget products that are used in electric arc furnace steel mills. Steel Dynamics, Inc. was founded in 1993 and is headquartered in Fort Wayne, Indiana.

Cree, Inc. (CREE) had a active trading with around 11.42M shares changing hands compared to its three month average trading volume of 1.02M. The stock traded between $28.22 and $31.64 before closing at the price of $28.83 with 5.18% change on the day. The Durham North Carolina 27703 based company is currently trading 38.94% above its 52 week low of $20.75 and -12.42% below its 52 week high of $32.92. Both the RSI indicator and target price of 67.82 and $24.82 respectively, lead us to believe that it should be put on hold over the coming weeks.

Cree, Inc. provides lighting-class light emitting diode (LED), lighting, and semiconductor products for power and radio-frequency (RF) applications in the United States, China, Europe, South Korea, Japan, Malaysia, Taiwan, and internationally. Its Lighting Products segment offers LED lighting systems and bulbs for use in settings, such as office and retail space, restaurants and hospitality, schools and universities, manufacturing, healthcare, airports, municipal, residential, street lighting and parking structures, and other applications. This segment sells its products to distributors, retailers, and customers. The company’s LED Products segment provides blue and green LED chip products for use in various applications, including video screens, gaming displays, function indicator lights and automotive backlights, headlamps, and directional indicators. It also offers XLamp LED components and LED modules for lighting applications; and surface mount and through-hole packaged LED products for video, signage, general illumination, transportation, gaming, and specialty lighting applications. In addition, this segment provides silicon carbide (SiC) materials for RF, power switching, gemstones, and other applications. Its Power and RF Products segment offers SiC-based power products consisting of Schottky diodes, SiC metal semiconductor field-effect transistors, and SiC power modules for use in power supplies used in computer servers, solar inverters, uninterruptible power supplies, industrial power supplies, and other applications. This segment also provides gallium nitride (GaN) high electron mobility transistors (HEMTs) and monolithic microwave integrated circuits (MMICs) for military, telecom, and other commercial applications; and custom die manufacturing services for GaN HEMTs and MMICs. Cree, Inc. was founded in 1987 and is headquartered in Durham, North Carolina.

ARIAD Pharmaceuticals, Inc. (ARIA) traded within a range of $23.7 to $23.76 after opening the day at $23.73. The company has seen its stock increase in value by 90.68% so far this year. The stock was down close to -0.08% on active volume in last trading session and closed at $23.72 per share. After the recent fall, the stock is currently holding -0.38% below its 52 week high of $23.81 and 442.79% above its 12-month low of $4.37. The shares are up by over 153.15% in the last three months, and the RSI indicator value of 88.39 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

 

Momentum Stocks in Focus: Exxon Mobil Corporation (XOM), ARIAD Pharmaceuticals, Inc. (ARIA), Alcoa Corporation (AA)

Exxon Mobil Corporation (XOM) managed to rebound with the stock climbing 0.14% or $0.12 to close the day at $85.09 on active trading volume of 11.83M shares, compared to its three month average trading volume of 11.18M. The Irving Texas 75039 based company has been outperforming the major integrated oil & gas group over the past 52 weeks, with the stock gaining 19.08%, compared to the industry which has advanced 40.54% over the same period. With RSI of 37.73, the stock should still continue to rise and get closer to its one year target estimate of $88.87, making it a hold for now.

Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products. As of December 31, 2015, the company had approximately 35,909 gross and 30,114 net operated wells. Exxon Mobil Corporation was founded in 1870 and is headquartered in Irving, Texas.

ARIAD Pharmaceuticals, Inc. (ARIA) grew with the stock adding 0.13% or $0.03 to close at $23.74 on active trading volume of 11.68M compared its three months average trading volume of 10.29M. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 324.69% up for the period and up by 90.84% so far this year. With price target of $20.63 and a 443.25% rebound from 52-week low, ARIAD Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States. The company has license agreements with Medinol Ltd. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Alcoa Corporation (AA) continued its upward trend with the stock climbing 3.33% or $1.21 to close the day at $37.5 on lower than average trading volume of 11.58M shares, compared to its three month average trading volume of 4.61M. The New York New York 10022 based company has been outperforming the aluminum companies by 79.1646% for last three months and its recent gains have pushed the stock slightly up 33.55% YTD, versus the aluminum industry which is up 27.12% for the same period. The RSI of 76.68 indicates the stock is overbought at the current levels, sell for now.

Alcoa Corporation engages in mining and production of bauxite, alumina, and aluminum products. It owns seven bauxite mines located near principal Atlantic and Pacific markets; and provides smelter grade alumina to aluminum manufacturers in Asia, the Middle East, and Latin America, as well as non-metallurgical grade alumina for industrial chemical operations in North America, Latin America, Europe, and Asia. The company is also involved in mining, refining, smelting, casting, and rolling aluminum products; production of aluminum billets, foundry ingots, rolling slabs, rods, powders, and proprietary alloys; and generation and sale of renewable energy. In addition, it produces and sells rolled aluminum sheets used in packaging, including aluminum bottles and food cans. The company was formerly known as Alcoa Upstream Corporation and changed its name to Alcoa Corporation in October 2016. Alcoa Corporation is based in New York, New York.